Theravance Biopharma officer sells 13,314 shares at ~$17

Available on EDGAR 09/17/2026 - 05:52 PM EDT Accepted by SEC EDGAR 09/17/2026 - 05:52 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Theravance Biopharma, Inc. (TBPH) reported that officer Rhonda Farnum, Senior Vice President of Commercial and Medical Affairs, sold a total of 13,314 ordinary shares on September 15, 2026 in a series of open-market transactions at weighted average prices of about $17.03 per share, executed under a Rule 10b5-1 trading plan dated September 3, 2025. The trades were carried out in multiple lots within a price range from $17.02 to $17.06 per share.

Insider Trade Summary 10b5-1

Net Seller: 13,314 shares

Net Sell 3 txns

Insider Farnum Rhonda

Role SVP, COMM & MEDICAL AFFAIRS

Sold 13,314 shs ($227K)

Share of Position Sold 5.9%

Type	Security	Shares	Price	Value
Sale	Ordinary Shares F1	3,329	$17.0341	$57K
Sale	Ordinary Shares F1	3,328	$17.0343	$57K
Sale	Ordinary Shares F1	6,657	$17.0342	$113K

Holdings After Transaction: Ordinary Shares — 213,476 shares (Direct)

Holdings Before and After: Ordinary Shares, 226,790 to 213,476 shares (Direct)

Footnotes (1)

1. F1. This transaction was executed in multiple trades at prices from $17.02 to $17.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Total shares sold: 13,314 shares First sale tranche: 3,329 shares at $17.03 per share Second sale tranche: 3,328 shares at $17.03 per share +3 more

6 metrics

Total shares sold 13,314 shares Aggregate ordinary shares sold on September 15, 2026 by the reporting officer

First sale tranche 3,329 shares at $17.03 per share One of three reported sale lots on September 15, 2026

Second sale tranche 3,328 shares at $17.03 per share One of three reported sale lots on September 15, 2026

Third sale tranche 6,657 shares at $17.03 per share Largest of the three reported sale lots on September 15, 2026

Price range of trades $17.02–$17.06 per share Range of prices at which multiple trades were executed for the reported sales

Rule 10b5-1 plan date September 3, 2025 Date of the trading plan under which the reported sales were executed

Key Terms

Rule 10b5-1 plan, weighted average sale price, open market or private transaction

3 terms

Rule 10b5-1 plan regulatory

"These transactions were executed in accordance with the reporting person's 10b5-1 plan dated 09/03/2025."

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the insider involved in the latest Form 4 for TBPH?

The filing reports transactions by Rhonda Farnum, who serves as Senior Vice President, Commercial and Medical Affairs at Theravance Biopharma, Inc. The transactions involve sales of the company’s ordinary shares reported on September 15, 2026.

How many Theravance Biopharma (TBPH) shares did the officer sell?

The officer sold a total of 13,314 ordinary shares of Theravance Biopharma, Inc. This total reflects three separate sale transactions reported for September 15, 2026.

On what date were the TBPH insider share sales executed?

All reported sales were executed on September 15, 2026. The transactions involved multiple trades on that date in the company’s ordinary shares.

What prices were received in the TBPH insider share sales?

The reported weighted average sale prices were about $17.03 per share, with individual trades executed in a price range from $17.02 to $17.06 per share, as disclosed in the footnote to the Form 4.

Were the TBPH insider sales made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states that the transactions were executed in accordance with the reporting person’s Rule 10b5-1 trading plan dated September 3, 2025, indicating the sales were pre-arranged under that plan.

What types of securities were sold in the TBPH Form 4 filing?

The Form 4 reports sales of ordinary shares of Theravance Biopharma, Inc. All three transactions on September 15, 2026 relate to this same class of security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farnum Rhonda

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, COMM & MEDICAL AFFAIRS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/15/2026		S		3,329	D	$17.0341(1)	223,461	D
Ordinary Shares	09/15/2026		S		3,328	D	$17.0343(1)	220,133	D
Ordinary Shares	09/15/2026		S		6,657	D	$17.0342(1)	213,476	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices from $17.02 to $17.06. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

These transactions were executed in accordance with the reporting person's 10b5-1 plan dated 09/03/2025.

	/s/ Brett A. Grimaud, Attorney-in-Fact	09/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)